PSMA-TRACIr

N/A

Report date: 2026/03/19 17:03:52

Base Information

Drug NamePSMA-TRACIr

Drug Alias NamePSMA-TRACIr

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT-cell-specific surface glycoprotein CD28 modulatorsProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane AntigenT-cell-specific surface glycoprotein CD28

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesJanux Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesJanux Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A